Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells-Reference-Cited by-同舟云学术

Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells

Published:2008-10-22 Issue:6 Volume:58 Page:915-930
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Karagiannis Panagiotis,Singer Josef,Hunt James,Gan Samuel K. E.,Rudman Sarah M.,Mechtcheriakova Diana,Knittelfelder Regina,Daniels Tracy R.,Hobson Philip S.,Beavil Andrew J.,Spicer James,Nestle Frank O.,Penichet Manuel L.,Gould Hannah J.,Jensen-Jarolim Erika,Karagiannis Sophia N.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-008-0607-1.pdf

Reference57 articles.

1. Rubin I, Yarden Y (2001) The basic biology of HER2. Ann Oncol 12(Suppl 1):S3–S8

2. Kaptain S, Tan LK, Chen B (2001) Her-2/neu and breast cancer. Diagn Mol Pathol 10:139–152

3. Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl 2):1–13

4. Landgraf R (2007) HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks. Breast Cancer Res 9:202

5. Hortobagyi GN (2005) Trastuzumab in the treatment of breast cancer. N Engl J Med 353:1734–1736

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic mutational analysis reveals an essential role of N275 in IgE stability;Biotechnology and Bioengineering;2024-08-20

2. Therapeutic Monoclonal Antibodies against Cancer: Present and Future;Cells;2023-12-14

3. A Fully Human IgE Specific for CD38 as a Potential Therapy for Multiple Myeloma;Cancers;2023-09-13

4. Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain;International Journal of Molecular Sciences;2023-07-27

5. Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial;Nature Communications;2023-07-25